Overview

A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

Status:
Not yet recruiting

Trial end date:
2022-06-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Itraconazole
Rifampin